Close Menu

NEW YORK – PerkinElmer announced on Wednesday that it has received the CE-IVD mark for its screening assay that simultaneously tests for spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID), and X-linked agammaglobulinemia (XLA) in newborns.

The assay, called Eonis, leverages RT-PCR technology, which when integrated into the Waltham, Massachusetts-based firm's newborn screening workflow provides labs a complete, single-source solution, PerkinElmer said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.